Comparative Pharmacology
Head-to-head clinical analysis: FENTANYL 12 versus QOLIANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENTANYL 12 versus QOLIANA.
FENTANYL-12 vs QOLIANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a synthetic opioid agonist primarily acting on mu-opioid receptors in the central nervous system, leading to analgesia, sedation, and respiratory depression.
QOLIANA (elagolix) is a nonpeptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist that competitively binds to GnRH receptors in the pituitary gland, thereby reducing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to decreased ovarian production of estrogen and progesterone, resulting in a hypoestrogenic state.
Transdermal: 12 mcg/hour applied every 72 hours. For opioid-tolerant patients only.
Initiate at 5 mg orally once daily, increase as tolerated to 10 mg once daily. Maximum dose 20 mg once daily.
None Documented
None Documented
Terminal elimination half-life is 3–12 hours (mean ~7 hours) in adults. Prolonged in elderly, hepatic impairment, and obesity (up to 20 hours). Context: half-life increases with continuous infusion (context-sensitive half-life).
Terminal elimination half-life is 12 hours (range 10–15 hours) in healthy adults; may extend to 18–24 hours in patients with moderate hepatic impairment (Child-Pugh B).
Primarily hepatic metabolism (N-dealkylation and hydroxylation) with <10% excreted unchanged in urine. Renal excretion accounts for ~75% of total elimination as metabolites; fecal excretion ~9%.
Renal excretion of unchanged drug accounts for approximately 30% of elimination; biliary/fecal excretion accounts for 60% (including metabolites); 10% is metabolized with negligible pulmonary elimination.
Category D/X
Category C
Opioid Agonist
Opioid Agonist